BioCryst to buy Astria Therapeutics in $700 million deal

Core Viewpoint - BioCryst Pharmaceuticals is acquiring Astria Therapeutics in a cash-and-stock deal valued at approximately $700 million, aiming to enhance its portfolio of treatments for rare diseases [1] Company Summary - The acquisition is part of BioCryst Pharmaceuticals' strategy to expand its offerings in the rare disease treatment market [1] - The deal is structured as a combination of cash and stock, indicating a significant investment in Astria Therapeutics [1] Industry Summary - The move reflects a growing trend in the pharmaceutical industry towards consolidation, particularly in the niche market of rare diseases [1] - This acquisition may position BioCryst Pharmaceuticals more competitively within the rare disease sector, potentially leading to increased market share and innovation in treatment options [1]